Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Obagi Medical

Also known as: Obagi, Obagi Nu-Derm

Obagi Medical is a skincare brand with product ranges for pigmentation, acne, sun-related skin changes and daily care. Its portfolio includes cosmetic products and preparations used in medical treatment plans. The ingredients, evidence and supply requirements depend on the exact product and market.

In plain English — Obagi Medical offers different products for concerns such as uneven colour, acne and dry skin. Some of its treatment combinations have improved skin concerns in studies, while other products serve everyday skincare roles. The right choice depends on the ingredients, your skin and whether medical supervision is needed.

Evidence status

Manufacturer-supported

Clinical evidence for selected formulations and regimens. Published studies report benefits from particular pigmentation and acne regimens, with differing designs and commercial relationships. A controlled resurfacing study did not show an added healing benefit over another active regimen. Findings belong to the tested products and combinations, not the brand as a whole.

What Obagi Medical is, and the types available#

Obagi Medical is a skincare business whose portfolio combines daily cosmetic care with products used in medical treatment plans. Its history dates to 1988. Bridgepoint completed acquisition of the Obagi business on 30 July 2026, so older ownership descriptions should be dated rather than carried forward as current.[1][2]i

The principal product distinctions useful in consultation include:

  • Nu-Derm: a system name associated with pigmentation care. The US prescription range lists named 4% hydroquinone products, while the Fx products documented in the supplier catalogue use arbutin.[6, 8][7, 8, 9]i
  • Professional-C: L-ascorbic-acid products offered for cosmetic antioxidant and appearance goals. The catalogue lists several concentrations; that is a formulation description, not a clinical ranking.[6, 8]
  • CLENZIderm: acne products, including a US-labelled 5% benzoyl-peroxide Therapeutic Lotion.[6, 7, 20]i
  • ELASTIderm, retinol and hydration products: distinct cosmetic preparations aimed at concerns such as the appearance of firmness, texture or dryness. Their actual ingredients and instructions should be checked individually.[6, 8]

Company and supply identity

Obagi Medical and ZO Skin Health are separate businesses and product families. Obagi Medical’s historical statutory filing records the end of Dr Zein Obagi’s services agreement in October 2010 and his shareholding on 30 November 2010. Shared history does not make one company’s products the other’s.[2]i

Healthxchange describes its UK distribution of Obagi Medical. Its legal notice identifies Healthxchange Pharmacy UK Limited, company 01999872, and Companies House corroborates the registered entity. Those sources establish the described supply role, not brand ownership or an exclusive contract.[3, 4, 5]i

Use of Obagi Medical in aesthetic practice#

The practical distinction is between supporting everyday skincare and managing a diagnosed condition with medicines. A practitioner can discuss cosmetic cleansing, moisturising and appearance goals within their competence; melasma treatment or an acne medicine plan requires the relevant clinical assessment and supply pathway.[7, 13, 15]i[6, 7, 13, 16, 20]i

For a medicine, check the exact pack, classification and authorised supply route. MHRA classification is product-specific; a US Rx listing is not proof of UK authorisation for the same preparation. Prescribed hydroquinone-containing pigment treatment should be supervised and reviewed rather than treated as an indefinite retail routine. The hydroquinone and retinoids entries cover the ingredient-level clinical context.[7, 13, 15]i

Cosmetics have their own requirements. Great Britain uses its applicable cosmetics framework; Northern Ireland follows the relevant EU-aligned framework under the Windsor Framework. Use the requirements and label for the actual market rather than assuming a US website or a GB catalogue settles NI compliance.[15, 17, 18]i

Professional distribution and product training support product familiarity, but do not grant a prescribing qualification or substitute for a diagnosis. Keep the consultation focused on the person’s concern and the evidence for the chosen preparation.[7, 13, 15]i[6, 7, 13, 16, 20]i

Contraindications and cautions#

Pregnancy and pregnancy planning:MHRA advises against topical retinoid medicines during pregnancy or when planning a pregnancy as a precaution. BAD also advises avoiding hydroquinone in pregnancy. A brand’s old US pregnancy-category wording should not replace the relevant UK advice. This does not mean every cleanser or moisturiser in the portfolio has the same restriction; assess its ingredients.[13, 14]

Ingredient allergy: avoid the implicated product. Named Nu-Derm preparations contain sodium metabisulfite, and their safety information warns of potentially serious allergic-type reactions in susceptible people. Ask about previous product reactions and check the full ingredient list, not only the headline active.[7, 8]

Inflamed or sunburned skin and concurrent treatment: the tretinoin information warns of irritation and particular caution with eczematous skin. The named BPO lotion warns that concurrent acne products can increase dryness or irritation. Review the entire routine and any prescriber instructions before adding another active.[7, 13, 20]i

Clinical uses and the evidence behind them#

Facial melasma

Gold and colleagues followed 37 women with facial epidermal melasma, mean age 46, phototypes III–VI, using a Nu-Derm system containing 4% hydroquinone plus 0.05% tretinoin. Thirty-four completed 12 weeks; 27 entered an optional extension and 25 completed 24 weeks. Melasma severity, pigment intensity and quality-of-life measures improved from baseline. The study was open-label and had no comparator, so it does not isolate an individual bottle’s contribution.[9]

OMP funded the study. The clinical authors disclosed investigator and/or consultancy/speaking relationships, and one author was an employee with stock and options. The positive findings concern that medically supervised combination in those women, not all pigmentation or every Nu-Derm formulation.[9]

Pigmentation and photoageing compared with another regimen

Fabi and Goldman reported a 12-week randomised facial comparison with 36 female completers: 16 using a hydroquinone-free SkinMedica regimen and 20 using hydroquinone-containing Obagi Nu-Derm. Both improved pigmentation and photoageing measures; between-regimen differences were not significant. The authors concluded that the tested regimens were comparably effective and tolerable. The retrieved original abstract did not provide full age/phototype details or funding/conflict declarations.[12]

Mild to moderate acne

Green and Del Rosso’s four-week randomised study enrolled 22 people, with 21 completing, predominantly women, with mild to moderate facial acne and normal-to-dry skin. Eligibility was ages 12–45. The tested three-step 5% BPO-lotion system and a 5% BPO/1% clindamycin regimen both reduced inflammatory and non-inflammatory lesions; the authors concluded that efficacy and tolerability were comparable. This small, short comparison was not a formal equivalence trial.[10]i

Del Rosso disclosed consulting, speaking and research relationships with Obagi and other companies; a separate study-funding statement was not found. The historical formulation and accompanying cleanser/moisturiser remain part of the intervention. Use the current acne pathway to decide treatment, rather than treating a brand trial as a replacement for it.[10]i[13, 16, 19]i

Care around facial resurfacing

The SPAR randomised trial enrolled 56 women with phototypes I–IV, with 46 followed beyond re-epithelialisation. Mean ages in the analysed groups were 49 and 55. It compared Nu-Derm with another active skincare regimen for four weeks before and ten weeks after facial resurfacing; both groups used hydroquinone and tretinoin. There was no significant healing-time or pigment advantage with Nu-Derm, and pre-procedure redness was greater. Recruitment fell below the planned target, limiting precision.[11]

An unrestricted Obagi grant funded the work, but the investigators expressly retained control of design, data and publication; the company did not review or edit the manuscript. Industry funding and sponsor control are different facts. This result concerns an adjunct to resurfacing, not every cosmetic use of the brand.[11]

These treatment exposures describe the research, not a recommended home regimen or preparation protocol for a peel or laser procedure.

Selecting an Obagi Medical product#

Start with the concern and diagnosis where required. Then identify the complete product name, ingredients, strength, market and whether medical supervision is needed. Record the existing routine and previous reactions so that product stacking does not obscure the cause of improvement or irritation.[6, 7, 13, 16, 20]i

An appearance goal such as dryness or texture is different from treating melasma or active acne. Agree an outcome and review point, and select a preparation the person can use within its instructions and any prescriber plan. Photoprotection remains part of pigmentation care, whichever brand is chosen.[6, 7, 13, 16, 20]i

For a planned procedure, the treating clinician’s instructions govern preparation and recovery. The general chemical-peel guide covers procedure selection; the product catalogue is not a substitute for that assessment.[11][6, 7, 13, 16, 20]i

Adverse effects and their management#

Irritation can include redness, burning, dryness, peeling or swelling. Severe or persistent symptoms warrant stopping the provoking exposure and seeking appropriate clinical or prescriber advice, rather than adding more exfoliation. The US BPO label also warns about bleaching of hair and dyed fabrics.[7, 13, 20]i[7, 20]i

In the melasma study, four of 37 women had probably or definitely treatment-related events. Average irritation scores were low, but assessments of erythema, dryness, peeling and stinging ran only to week 12. Sixteen of 37 used permitted hydrocortisone, eight preventively and eight for symptoms. The favourable tolerability therefore describes a supported research regimen, not an entirely steroid-free exposure. This is not an instruction to self-treat irritation with a steroid.[9]

Unwanted pigment change during hydroquinone treatment needs clinical review: BAD describes both excessive lightening and occasional darkening. Review the diagnosis, exposure and prescriber plan rather than continuing solely because the product was intended to brighten skin.[13, 16, 19]i

Possible allergyshould prompt discontinuation of the suspected product and assessment. Rapid breathing difficulty, throat swelling or other signs of anaphylaxis require emergency care—call 999.[7, 8][13, 16, 19]i

Referral and scope boundaries#

Uncertain pigmentation, a changing mole or a changing patch of skin should be assessed medically before another brightening product is selected. Melasma management involves diagnosis, light protection and supervised treatment where indicated; a product name is not a diagnosis.[13, 16, 19]i

Refer through the appropriate acne pathway for diagnostic uncertainty, nodulocystic disease, developing scars, persistent pigment changes or significant distress. A client buying increasingly complex routines may need a clinical review rather than another brand substitution.[13, 16, 19]i

Aesthetic skincare advice should support, not independently alter, prescribed treatment. Pregnancy questions, significant reactions and decisions about a medicine belong with an appropriate healthcare professional.[13, 14][7, 13, 15]i

Mechanism of action#

The portfolio has several mechanisms because it contains different ingredients. Hydroquinone reduces new pigment production; tretinoin is a retinoid medicine used in clinical skin treatment; BPO is an acne active. Their broader evidence is covered in the linked hydroquinone, retinoids and benzoyl-peroxide entries.[6, 7, 13, 20]i

Cosmetic products also use familiar formulation roles: moisturising ingredients, exfoliating acids and antioxidants such as L-ascorbic acid. The catalogue describes ingredients including glycerin, emollients, glycolic/lactic acids and vitamin C across different products. A named blend’s proposed action should be explained as that formulation’s rationale, not a single biological property of everything called Obagi.[6, 7, 13, 20]i

Commonly misstated claims#

A prescription-system trial transferred to Fx

Claim heard:“The hydroquinone Nu-Derm trial proves Clear Fx gives the same result.”

Literature finding: The clinical regimen used 4% hydroquinone with tretinoin and other products. Current Clear Fx has an arbutin-based ingredient list. They are different exposures despite the shared Nu-Derm name.[7, 8, 9]i

Supported statement: Match the trial to the actual formulation and combination; a hydroquinone-regimen result cannot simply be assigned to Fx.

Irritation used as an efficacy score

Claim heard:“The more peeling and redness, the better the system is working.”

Literature finding: The product safety information describes marked irritation as a reason for adjustment, discontinuation or clinical assessment. It does not validate peeling severity as a measure of treatment success.[7, 20]i

Supported statement: Judge the intended skin outcome and tolerability separately; an adverse reaction is not a target.

A regimen comparison turned into a brand ranking

Claim heard:“A comparison with one Obagi system tells us which whole skincare brand is best.”

Literature finding:Fabi and Goldman’s trial compared two specified regimens in women with facial pigmentation over 12 weeks. It did not test every product in either portfolio or any ZO regimen.[2, 12]i

Supported statement:Comparative findings apply to the tested products, population and outcome—not a universal brand league table.

Areas of remaining uncertainty#

  • How closely does today’s formulation match the study product? Check the exact product/version before using an older study to explain expected benefit.[6, 7, 8, 9, 10, 11, 12]
  • Which part of a multi-product routine is responsible for a change? Record the complete exposure and review one agreed concern rather than attributing everything to the headline ingredient.[9, 10, 11, 12]
  • How should care evolve after initial improvement? Discuss maintenance, sun protection and review with the appropriate clinician rather than treating a research course as a permanent routine.[13]

Frequently asked questions#

What should a client bring to a product consultation?

The exact names or packaging of current products, details of prescribed treatment, allergy history and the concern they want to address. Similar system names can contain different actives.[6, 7, 8, 13]

Does every Obagi product require a prescription?

No. The portfolio includes cosmetic products as well as preparations used in medical treatment. The exact product and local supply classification determine the requirement.[6, 7, 20]i[7, 13, 15]i

Can professional skincare replace acne assessment?

It can support an appropriate plan, but significant or uncertain acne needs the clinical pathway described above. Product selection should follow the assessment, not delay it.[13, 16, 19]i

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Waldencast/Bridgepoint. Closing announcement for the sale of the Obagi business. Exhibit 99.1 to Waldencast Form 6-K, 30 July 2026.Tier 4Supports: Completed Bridgepoint acquisition of Obagi on 30 July 2026, not merely an announced transaction; current corporate identity, not clinical endorsement.Funding / interest: Corporate transaction announcement filed with the SEC; commercial source.
  2. Obagi Medical Products Inc. Form 10-K for the year ended 31 December 2012. Business overview and note 9. Filed 2013.Tier 4Supports: Company began in 1988; historical separation from Dr Zein Obagi, whose services agreement ended in October 2010 and shareholding ended 30 November 2010; distinction from ZO. Historical product descriptions are not current authorisations.Funding / interest: Company-authored statutory filing, primary for its reported history; not independent clinical evidence.
  3. Healthxchange. Corporate website and brand-distribution description. Accessed 16 September 2026.Tier 4Supports: Current UK supplier describes its distribution of Obagi Medical. No exclusivity or brand ownership inferred.Funding / interest: Commercial distributor website.
  4. Healthxchange. Privacy notice, clause 1.1. Accessed 16 September 2026.Tier 4Supports: Identifies site operator Healthxchange Pharmacy UK Limited, company 01999872, linking the trading-site role to its registered entity.Funding / interest: Commercial company's own legal notice.
  5. Companies House. Healthxchange Pharmacy UK Limited, company 01999872. Overview accessed 16 September 2026.Tier 1Supports: Active company identity matches the supplier's legal notice. The register alone does not establish a distribution contract.Funding / interest: Public corporate register; not clinical evidence.
  6. Obagi / Healthxchange. Obagi Product Catalogue. Undated UK-supplier PDF, accessed 16 September 2026.Tier 4Supports: Range architecture and stated ingredients/purposes, including Nu-Derm Fx, Professional-C, ELASTIderm, retinol and hydration products. Not an independent trial or confirmation of every current UK authorisation.Funding / interest: Brand promotional catalogue hosted by its commercial supplier.
  7. Obagi. Obagi Rx Transformational Skincare: products, ingredients and important safety information. US website, accessed 16 September 2026.Tier 4Supports: Named US hydroquinone/tretinoin products, ingredient allergy/sulfite warnings, irritation and sunscreen precautions. US listing is not UK marketing authorisation; old US pregnancy wording is not substituted for MHRA guidance.Funding / interest: Manufacturer's commercial and product-safety information.
  8. Obagi. Nu-Derm Clear Fx Skin Brightening Cream. Product page and ingredient list, accessed 16 September 2026.Tier 4Supports: Arbutin-based Clear Fx ingredient identity, distinct from 4% hydroquinone Clear; AHA sun warning. Not a controlled efficacy study.Funding / interest: Manufacturer product page; customer reviews and AI review summaries are not used as evidence.
  9. Gold M, Rendon M, DiBernardo B, Bruce S, Lucas-Anthony C, Watson J. Open-Label Treatment of Moderate or Marked Melasma with a 4% Hydroquinone Skin Care System Plus 0.05% Tretinoin Cream. J Clin Aesthet Dermatol. 2013;6(11):32–38. PMID:24307923.Tier 3Supports: Thirty-seven women, mean age 46, phototypes III–VI, facial epidermal melasma; 34 completed 12 weeks, 25 completed optional 24 weeks. Positive before/after severity and quality-of-life outcomes, no comparator; adverse effects and permitted hydrocortisone use.Funding / interest: OMP funded the study. Clinical authors disclosed investigator and/or consultancy/speaking relationships; Watson was an OMP employee with stock/options. Medical writing acknowledged.
  10. Green LJ, Del Rosso JQ. Efficacy and Tolerability of a Three-Step Acne System Containing a Solubilized Benzoyl Peroxide Lotion versus a Benzoyl Peroxide/Clindamycin Combination Product: An Investigator-Blind, Randomized, Parallel-Group Study. J Clin Aesthet Dermatol. 2008;1(3):16–20. PMID:21203357.Tier 2Supports: Twenty-two enrolled/21 completed, eligibility 12–45, mainly women, mild/moderate facial acne and normal-to-dry skin; four-week comparison of named 5% BPO lotion system with 5% BPO/1% clindamycin regimen. Both improved; not formal equivalence for all products.Funding / interest: Del Rosso disclosed consulting, speaking and research relationships with Obagi and several other companies. Green was an investigator. Separate study funding was not explicitly stated in the retrieved paper.
  11. Pannucci CJ, Reavey PL, Kaweski S, et al. A Randomized Controlled Trial of Skin Care Protocols for Facial Resurfacing: Lessons Learned from the Plastic Surgery Educational Foundation's Skin Products Assessment Research Study. Plast Reconstr Surg. 2011;127(3):1334–1342. doi:10.1097/PRS.0b013e318204361d. PMID:21364435.Tier 2Supports: Fifty-six women randomised, 46 followed beyond re-epithelialisation, phototypes I–IV; four weeks before/ten weeks after facial resurfacing. Both arms received HQ/tretinoin; no significant healing advantage, limited recruitment and higher pre-procedure redness with Nu-Derm.Funding / interest: Unrestricted Obagi grant to PSEF; authors explicitly state company did not design, collect, analyse or review/edit the manuscript. No author financial interest in products declared. Pannucci also had NIH salary support.
  12. Fabi SG, Goldman MP. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging. J Drugs Dermatol. 2013;12(3):S32–S37. PMID:23545931.Tier 2Supports: Original MEDLINE abstract retrieved via Europe PMC: 36 female completers, 16 SkinMedica/20 Obagi, 12 weeks, facial mottled pigment/photoageing. Both improved without significant between-regimen differences; full population/funding detail unavailable.Funding / interest: Funding and full conflict declarations not available in the retrieved original abstract; independence not inferred.
  13. British Association of Dermatologists. Melasma. Patient information leaflet, updated June 2024.Tier 4Supports: Diagnosis, light protection, medically supervised pigment treatments, pregnancy avoidance, irritation/unwanted pigment change and review of changing lesions.Funding / interest: Professional-association patient consensus leaflet; no product sponsor stated.
  14. MHRA. Oral retinoid medicines: revised and simplified pregnancy prevention educational materials for healthcare professionals and women. 19 June 2019, subsection on topical retinoids.Tier 1Supports: Topical retinoid medicines contraindicated during pregnancy as precaution; avoid when planning pregnancy. Oral Pregnancy Prevention Programme requirements are not transferred to topicals.Funding / interest: UK medicines-regulator safety advice.
  15. MHRA. Medicines: reclassify your product. Updated 3 September 2026.Tier 1Supports: Supply classification belongs to the medicine pack; POM, pharmacy and general-sale categories. Not a brand-wide medicine classification.Funding / interest: Official UK medicines-regulation guidance.
  16. NICE. Acne vulgaris: management. NG198 recommendations, updated 3 August 2026.Tier 1Supports: Established acne management and referral for uncertainty, nodulocystic disease, scars, pigment changes and distress; not a brand recommendation.Funding / interest: Publicly developed NICE guideline.
  17. OPSS. Regulation 1223/2009 and the Cosmetic Products Enforcement Regulations 2013: Great Britain. Updated 29 June 2026.Tier 1Supports: GB cosmetics framework and product-safety/claims obligations, distinct from medicinal classification and NI framework.Funding / interest: Official GB statutory guidance.
  18. OPSS. Regulation 1223/2009 and the Cosmetic Products Enforcement Regulations 2013: Northern Ireland. Updated 29 June 2026.Tier 1Supports: NI cosmetics framework follows applicable EU rules under the Windsor Framework; no GB-only rule transferred.Funding / interest: Official Northern Ireland-specific statutory guidance.
  19. NHS. Anaphylaxis. Accessed 16 September 2026.Tier 4Supports: Emergency recognition and 999 response for suspected anaphylaxis; public patient information, not a formal graded guideline.Funding / interest: NHS public information; no commercial sponsor stated.
  20. Obagi Cosmeceuticals LLC. CLENZIDERM Therapeutic Lotion Drug Facts label. Revised January 2025; DailyMed record accessed 16 September 2026.Tier 4Supports: Named US 5% benzoyl peroxide acne-lotion ingredients, sensitivity exclusions, irritation/sun/fabric-bleaching warnings. A US label, not UK authorisation or independent comparative evidence.Funding / interest: Manufacturer-submitted product label hosted by the US National Library of Medicine.